immune thrombocytopenia purpura

immune thrombocytopenia purpura

Immune thrombocytopenia purpura is an acquired hematologic disorder characterized by isolated thrombocytopenia resulting from immune-mediated platelet destruction and impaired platelet production. It presents in both children and adults, with acute forms often following viral infections and chronic forms associated with autoimmune disease, lymphoid malignancy, or medication exposure. Management balances bleeding risk against treatment adverse effects and includes immunomodulation, targeted therapies, and, in refractory cases, surgical intervention.

Signs and symptoms

Patients commonly present with cutaneous and mucosal bleeding manifestations such as petechiae, ecchymoses, and spontaneous epistaxis. Other frequent findings include gingival bleeding, menorrhagia in reproductive-age women, and easy bruising apparent after minor trauma. Severe presentations can include gastrointestinal hemorrhage and life-threatening intracranial hemorrhage, which may be heralded by headache, focal neurologic deficits, or altered consciousness. Constitutional features such as fever, lymphadenopathy, or hepatosplenomegaly are uncommon in primary forms but may appear when associated with entities like Systemic lupus erythematosus, Human immunodeficiency virus, or Chronic lymphocytic leukemia.

Causes and pathophysiology

Pathogenesis involves autoantibody formation against platelet surface glycoproteins, often directed at GPIIb/IIIa or GPIb/IX complexes, leading to opsonization and enhanced phagocytosis by splenic macrophages. Impaired megakaryocyte function and antibody-mediated inhibition of thrombopoiesis in the bone marrow also contribute. Secondary causes include autoimmune disorders such as Rheumatoid arthritis, viral infections including Hepatitis C virus and Varicella zoster virus, lymphoproliferative disorders like Non-Hodgkin lymphoma, and drug-induced immune thrombocytopenia from agents such as heparin leading to heparin-induced thrombocytopenia distinct from primary immune thrombocytopenia. Genetic predisposition and environmental triggers intersect in complex ways; molecular mimicry following infections with agents like Epstein–Barr virus or Helicobacter pylori has been proposed. Immune dysregulation involving B-cell and T-cell subsets and cytokines observed in studies of Interleukin-10 and Interferon-gamma supports a multifactorial autoimmune basis.

Diagnosis

Diagnosis is clinical and laboratory-based, established by isolated thrombocytopenia with a platelet count typically <100 × 10^9/L in the absence of other causes. Initial evaluation includes a complete blood count and peripheral blood smear to exclude pseudothrombocytopenia, hemolysis, or marrow infiltration as seen in Aplastic anemia or Acute lymphoblastic leukemia. Serologic testing for secondary causes often targets antibodies or antigens related to Human immunodeficiency virus, Hepatitis C virus, and autoimmune serologies for Systemic lupus erythematosus. Bone marrow examination is reserved for atypical cases, older adults, or those with cytopenias involving multiple lineages and can reveal normal or increased megakaryocytes. Tests for antiplatelet antibodies have limited sensitivity and specificity and are not required for diagnosis; platelet function assays and assays for platelet-associated IgG may be used in specialized centers. Assessment of bleeding severity employs standardized tools used in guidelines from organizations such as the American Society of Hematology.

Management and treatment

Therapy is individualized according to bleeding risk, platelet count, comorbidities, and patient preferences. First-line treatment for those with clinically significant bleeding or very low platelet counts typically includes corticosteroids such as prednisone or dexamethasone to reduce autoantibody production and macrophage activity. For urgent control of bleeding, intravenous immunoglobulin administration is used to raise platelet counts rapidly. Second-line and steroid-sparing options include thrombopoietin receptor agonists—eltrombopag and romiplostim—which stimulate megakaryopoiesis, and immunosuppressive agents such as rituximab that target CD20-positive B cells. Splenectomy remains an effective option for durable remission in selected patients, with surgical referrals considered in consultation with surgeons experienced in outcomes for procedures like laparoscopic splenectomy. Other modalities, including azathioprine, cyclosporine, danazol, and mycophenolate mofetil, are used in refractory disease. Management of secondary forms targets the underlying disorder, for example antiviral therapy for Hepatitis C virus or eradication therapy for Helicobacter pylori where associations are established. Platelet transfusions are reserved for life-threatening hemorrhage given rapid platelet destruction except when coupled with IVIG or antifibrinolytic agents such as tranexamic acid.

Prognosis and complications

Prognosis varies: many pediatric cases are self-limited with spontaneous remission following infections, whereas chronic disease in adults may persist and require long-term therapy. Major bleeding complications, particularly intracranial hemorrhage, drive morbidity and mortality; risk stratification considers age, comorbid conditions such as Hypertension and prior cerebrovascular disease including Ischemic stroke, and platelet trends. Long-term therapy carries risks including infection from immunosuppression, thromboembolic events reported with thrombopoietin receptor agonists and splenectomy, and steroid-related metabolic complications with prolonged use. Close follow-up with hematology services and coordination with primary care, surgical teams, and relevant specialists such as those in Neurology and Obstetrics and gynecology for pregnancy management optimizes outcomes. Ongoing research from institutions including the National Institutes of Health and professional bodies such as the British Society for Haematology continues to refine diagnostic criteria and therapeutic algorithms.

Category:Autoimmune diseases